Background: Many countries, mainly high-and upper-middle income, have implemented human papillomavirus (HPV) vaccination programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNApositive samples were additionally subjected to HPV E6*I mRNA detection and/or p16 INK4a immunohistochemistry. For cervical cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16 INK4a biomarkers.
HPV infection is unequivocally linked to almost all cervical cancer cases (95% of cases) and a large proportion of anal cancer cases (88% of cases attributable to HPV) (2) . HPV is also causally associated with a varying percentage of cancers of the vulva, vagina, penis, and a subset of HNCs, particularly tonsillar cancer (7, 8) . Within the spectrum of HPV oncogenic types, HPV 16 is the most prevalent in all HPV-related cancer sites. Based on previous analytical studies that demonstrated HPV to be a necessary cause of cervical cancer, HPV attribution has been based on the detection of HPV DNA alone. However, additional carcinogenic pathways other than HPV are suspected for anal and vaginal cancers, and validated for vulvar, penile, and HNCs. Thus, the identification of HPV DNA combined with E6/E7mRNA, a marker of viral transcriptional activity, or p16
INK4a , a cell surrogate marker of HPV carcinogenic transformation, provides a more accurate, although conservative, assessment of oncogenic activity of the virus in the specific sites (9) (10) (11) . Prophylactic HPV vaccines have been introduced worldwide since 2006, with a high efficacy and safety record in the prevention of vaccine-type HPV infection and disease. Further, the HPV vaccines show a high effectiveness profile on prevalent infections, precancerous lesions, and genital warts, as well as a robust herdprotection effect in nonvaccinated sexual partners with a high vaccine coverage rate (12, 13) . Currently, three HPV vaccines are commercially available (bivalent, tetravalent, and nonavalent). All three contain virus-like particles (VLPs) of HPVs 16/18. The tetravalent vaccine also contains VLPs from HPVs 6/11. The nonavalent vaccine additionally protects against HPVs 31/33/45/52/58.
The World Health Organization recognizes the importance of HPV-related diseases as global public health threats and has reiterated the recommendation to include HPV vaccines in national immunization programs (14) . By October 2014, 80 countries (mainly high-and upper-middle income) had implemented HPV vaccination programs and 47 million women had received the full course of the vaccine. Even more, it has been estimated that approximately 379 000 cases of cervical cancer and 156 000 deaths could be averted in the 47 million fully vaccinated women by age 75 years, assuming lifelong protection (15) .
The evidence suggests that the combination of high HPV vaccination coverage in adolescents together with high cervical screening coverage (followed by adequate treatment of the lesions detected by screening) can eliminate cervical cancer as a public health problem. As a result, it has been established that one of the greatest priorities and challenges in global health is to give access to HPV vaccination and cervical screening to the majority of women around the world. The availability of a wide range of cervical screening techniques (cytology, HPV-detection techniques, visual inspection with acetic acid) and HPV vaccination options (bivalent, tetravalent, and nonavalent vaccines with two-or three dose schedules) leads to an increase in the complexity of decision making regarding the combination of optimal prevention strategies in each region of the world.
To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease burden and to help formulate recommendations on HPV prevention, we estimated the HPV type distribution and burden of cancer cases attributable to the HPV types included in the nonavalent vaccine. For this we used new data derived from a large international study that provided information on HPV DNA, mRNA, and p16
INK4a from formalinfixed paraffin-embedded (FFPE) tissue of anogenital and HNC sites.
Materials and Methods
To estimate the prevalence and relative contribution (RC) of the types included in licensed HPV vaccines in HPV-related cancers, we used updated data from an international project designed and coordinated by the Catalan Institute of Oncology (ICO) (Barcelona, Spain) in collaboration with DDL Diagnostic Laboratory (Rijswijk, Netherlands) (5, (16) (17) (18) (19) (20) ADC-7% ADSC-2% SCC100NonWB-72% SCC100NonWB-51% SCC100NonWB -33% SCC100NonWB-64% SCC100NonWB-88% SCC100NonWB-96% SCC100NonWB-92% Other-2%
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Study Design
The project is a cross-sectional study. Case recruitment protocols were previously described (5, (16) (17) (18) (19) (20) . Briefly, consecutive (or randomly selected) FFPE specimens processed in pathology laboratories were obtained from hospital pathology archives in 50 countries (Figure 1 
Statistical Analysis
For cervical cancer, RC of the nine types included in the nonavalent vaccine was expressed as the proportion of women positive for a specific type among all HPV DNA-positive samples. HPV prevalence was calculated as those positive among all tested samples. For the other cancer sites, RC estimates were based on the combined positivity for HPV DNA and (E6*I mRNA or p16
INK4a
). HPV prevalence indicates those positive for HPV DNA and (E6*I mRNA or p16
) among all those tested. For all sites, information on multiple infections was added to single types in accordance with a proportional weighting attribution (22, 23) . RCs by region, sex, and age at diagnosis were determined. To evaluate differences among proportions, we used the most suitable test (chi-squared, Fisher), adjusting for multiple comparisons (Bonferroni-Holms) when necessary. Trend test analysis for proportions was used to evaluate trends by age at diagnosis. The statistically significant P value was set at .05.
We further estimated the potential preventable number of cases per year by applying the estimated proportions attributed to HPV to the number of cases estimated to occur each year as reported by de Martel et al. (24) .
Results
Squamous cell carcinomas (SCCs) accounted for more than 90% of cases reviewed, with the exception of vaginal cancer. Most cases were from Europe and the Americas (Table 1) . Cervical cancer cases were diagnosed at younger ages (mean age ¼ 51.1 years) compared to the other sites (mean ages ranging from 61.0 to 68.5 years).
Overall HPV and type-specific prevalence results are reported in Table 1 and "E6*I mRNAþ or p16
INK4a þ") for all types combined was 82.6% anal, 71.0% vaginal, 27.7% penile, 24.6% vulvar, 22.4% oropharyngeal, 4.4% oral cavity, and 3.5% laryngeal cancers. When comparing HPV DNA detection estimates to the ones adding E6*I mRNA and p16
INK4a
, a reduction of the proportion of cases attributed to HPV were higher for oral cavity and larynx (percentage reduction ¼ 40.5% and 38.6%, respectively) than penis, vulva, oropharynx, anus, and vagina (percentage reduction ¼ 16.3%, 14.0%, 10.0%, 6.4% and 4.4%, respectively), (P < .05 for oral cavity, larynx, penis, vulva, and anus).
Among HPV positives, RC of the nine types was 95.7% in the anus, followed by oropharynx (95.1%), vulva (92.8%), oral cavity (92.7%), cervix (89.3%), penis (88.1%), vagina (85.6%), and larynx (77.8%) (Tables 2 and 3 and Figure 2 (Tables 2 and 3) . HPV RCs by region are provided in Figure 4 and Supplementary Material Tables 2 and 3 (available online) (Figure 3) .
No specific nine HPV RC age trends were observed by cancer site, except in the cervix (Supplementary Material Table 4 , available online), where the combined RC of the nine types decreased with age (P < .001); mainly explained by the decrease of HPVs 16/ 18/45 in older ages (more details in Serrano et al. 2012 ) (25) .
The potentially preventable fraction of the nonavalent HPV vaccine would be around 50% worldwide, taking into account our type-specific prevalence estimates and the estimated number of incident cases at HPV-related cancer sites provided by de Martel et al. (24) . These would include most cervical and anal cancers and a substantial fraction of vaginal, penile, vulvar, and HNCs (Table 4) .
Discussion
This comprehensive analysis of the contribution of HPV vaccine types in selected anogenital and HNCs provides robust estimates to be used to monitor the vaccine impact worldwide. We present data from all HPV-related sites, updating the number of the cervical series, and adding the evaluation of molecular and immunohistochemistry markers of viral activity beyond HPV DNA detection. In the absence of a unique carcinogenic pathway and of detection of specific infections leading to cancer, the addition of these markers increases our ability to attribute causality (8, 11) . Our data confirm the biological role of HPV in the great majority of HPV DNA-positive anogenital and oropharyngeal cancers, and to a much lesser extent in oral cavity and laryngeal cancers.
We have estimated that the combined detection of HPV DNA and (E6*I mRNA or p16
INK4a
) confirms that the addition of HPVs 31/33/45/52/58 to the current vaccine types (HPVs 16/18/6/11), could prevent almost 96% of the HPV-positive cancers of the anus, vulva (93%), cervix (90%), penis (88%), vagina (86%), oropharynx (95%), oral cavity (93%), and larynx (78%). A marked heterogeneity in the incremental HPV-related preventable fraction added by the nonavalent vaccine compared to bivalent and tetravalent vaccines was observed, ranging from 8.0% (anal) to 21.0% (vaginal) in anogenital cancer sites, and from 1.8% (oral cavity) to 22.2% (larynx) in HNC sites.
Similar to previous data, overall HPV prevalence was lower for vulvar (24.6%), penile (27.0%), oral cavity (4.4%), laryngeal (5.7%), and oropharyngeal (22.4%) cancers, compared with vaginal (71.0%), anal (82.6%), and cervical (84.8%) cancers (2) . Therefore, overall the nonavalent vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal, and 90% of cervical cancer cases, 21.3% of oropharynx, 4.0% of oral cavity, and 2.7% of larynx cancers cases. Some of our prevalence estimates are lower than those published in previous metaanalyses (6, 26) or in series using similar protocols (27) (28) (29) (30) . These differences were expected, as we used a more restrictive protocol in terms of HPV attribution by adding additional markers. This study included cases from numerous countries, some of which had scarce data published. This is particularly relevant in HNC sites where a substantial variability in the HPV-related attribution has been observed across regions (2) . Contrary to this, our series have a distinctive limitation on samples from areas reported to have an increased trend of HPV-driven HNCs, such as the United States and Northern Europe, where higher attributable fractions in HNCs have been recently reported (30) . Although the exclusive use of HPV DNA results in higher attribution to HPV (30) , when adding other biomarkers the attribution was reduced to 67.2% in oropharynx SCC, 5.9% in oral cavity SCC, and 1.7% in larynx SCC (27-29). 
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Oropharynx (n=160) Penis (n=119) Anus ( Worldwide incidence rates at HPV-related cancer sites other than the cervix are much lower than that observed for cervical cancer. However, incidence rates in anal, vulvar, and HPV-related HNCs are increasing, probably linked to changes in sexual behavior, tobacco and alcohol consumption, and in cervical cancer screening policies (2) (3) (4) .The large contribution of HPV infection, mainly of HPV 16, the absence of wellestablished screening instruments, and algorithms for the detection of HPV-related cancer cases other than the cervix, and the current evidence on HPV vaccine efficacy, reinforces the role that HPV vaccines can play in primary prevention of HPV-related lesions. Moreover, even if a higher impact of HPV vaccination would be expected in cervical and anal cancer, the confirmed increasing trends of HNCs attributable to HPV could be translated to a high number of cases prevented by vaccination despite the low proportion of HPV-related cases estimated for these sites (2) .
HPV 16 was the most important oncogenic type (60% in anogenital cancer sites, and 44% to 91% in HNCs). The inclusion of additional markers increased the HPV 16 RC in vulvar, penile, oral cavity, and oropharyngeal cancers, and confirmed the causative role for other, less frequently occurring mucosal HPV types. Some non-HPV 16 types, usually involved in cervical cancer, are also related to other cancers of the genital tract and HNCs, but to a lesser extent. Although HPV18 is reported to be the second most common type in cervical cancer, variations were observed in other cancer sites. HPV 33 follows HPV 16 in vulvar and oropharyngeal cancers, HPV 31 in vaginal cancer, HPVs 31/45 in penile cancer, HPVs 18/33 in anal cancer, HPV 58 in oral cavity cancer, and HPVs 18/45 in laryngeal cancers. However, results in oral cavity and larynx should be interpreted with caution because of the limited number of cases included. HPVs 6/11, contribution is minimal in the overall burden of HPV-related cancers, although they still rank relatively high in penile and anal cancer.
We found little heterogeneity by geographical region, sex, and age at diagnosis. Regional differences in the HPV RCs were significant only for cervical and oropharyngeal cancers. For cervical cancer a significantly higher contribution was observed in Asia and Oceania, and for oropharyngeal cancer a significantly higher contribution was observed in Europe compared to the Americas. However, further research will be necessary to provide robust estimates by region for noncervical lesions. Overall, HPV RC estimates were higher in women than in men, although differences were significant only for oropharyngeal cancer. The magnitude of RCs decreased with increasing age for all cancer sites. RC age trends were evaluated for the nine types combined. A similar analysis for individual HPV types was not possible because of the limited number of cases in cancer sites other than the cervix. Assessment of multiple infections was possible by means of a proportional weighting attribution (22, 23) . A decrease in the proportion of cases with multiple infections was observed in oropharyngeal cancers. The proportion of cases with multiple infections (0.4%) was 15 times lower than in cervical cancer (6.3%). It is unknown why there is this difference in the proportion of multiple infections, but it could be explained by differences in cell susceptibility to HPV infection in different tissues.
Despite the large sample size and the strong design, this study is not free of limitations. The principal one is that while the presence of HPV DNA was assessed in all tested samples, the two additional biomarkers E6*I mRNA and p16
INK4a were assessed only in HPV DNA-positive samples as well as in a small fraction of HPV DNA-negative cases (of which 10% were mRNA positive), and not for all HPV genotypes. Therefore, we cannot completely rule out that we are not excluding some truly HPV-driven cases because of imperfect detection of the HPV DNA test, although we used the most sensitive test available to date. Moreover, although HPV E6*I mRNA and p16 INK4a together with HPV DNA are well established markers in research and even in clinical settings for specifically attributing one case to be etiologically related to the virus, we are missing other potential approaches such as laser capture microdissection that can specifically analyze the markers in tumoral cells instead of the whole paraffin-embedded tissue block section that may be even more specific. However, we have applied the most suitable markers analyses taking into account the design of the study, a large epidemiological biorepository. Another limitation of the study was the small number of samples included from some regions (such as Africa) and ages, thus restricting the validity of our results for certain regions and ages. Finally, the use of fresh tissue samples would have been preferred but unrealistic to obtain when including such a large number of countries. Additionally, the studies reflect the epidemiology of each country and the impact of potential variation in screening or other environmental modifications in HPV attribution is difficult to fully evaluate in this study. Finally, for the estimated preventable fraction we make several vaccine effects assumptions: efficacy for all HPV-related cancers, long-term duration of the protection, among others. Our estimations suggest that if HPV vaccination programs with the nonavalent HPV vaccine are effectively implemented, around 90% of cervical cancers and 50% of all HPV cancer sites related to HPV could be prevented.
